SI0972520T1 - Liofiliziran sestavek humanega kostnega morfogenetskega proteina MP52 - Google Patents

Liofiliziran sestavek humanega kostnega morfogenetskega proteina MP52

Info

Publication number
SI0972520T1
SI0972520T1 SI9830798T SI9830798T SI0972520T1 SI 0972520 T1 SI0972520 T1 SI 0972520T1 SI 9830798 T SI9830798 T SI 9830798T SI 9830798 T SI9830798 T SI 9830798T SI 0972520 T1 SI0972520 T1 SI 0972520T1
Authority
SI
Slovenia
Prior art keywords
freeze
bone morphogenetic
morphogenetic protein
dried composition
protein human
Prior art date
Application number
SI9830798T
Other languages
English (en)
Inventor
Mitsuko Inagaki
Hideki Hoechst Marion Ichikawa
Original Assignee
Bioph Biotech Entw Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioph Biotech Entw Pharm Gmbh filed Critical Bioph Biotech Entw Pharm Gmbh
Publication of SI0972520T1 publication Critical patent/SI0972520T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI9830798T 1997-01-30 1998-01-29 Liofiliziran sestavek humanega kostnega morfogenetskega proteina MP52 SI0972520T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1634997 1997-01-30
PCT/JP1998/000371 WO1998033514A1 (fr) 1997-01-30 1998-01-29 Composition lyophilisee de mp52 humaine de proteines morphogenetiques osseuses

Publications (1)

Publication Number Publication Date
SI0972520T1 true SI0972520T1 (sl) 2006-02-28

Family

ID=11913900

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830798T SI0972520T1 (sl) 1997-01-30 1998-01-29 Liofiliziran sestavek humanega kostnega morfogenetskega proteina MP52

Country Status (22)

Country Link
EP (1) EP0972520B9 (sl)
JP (1) JP4209948B2 (sl)
KR (1) KR100548107B1 (sl)
CN (1) CN1152712C (sl)
AP (1) AP983A (sl)
AT (1) ATE302021T1 (sl)
AU (1) AU737595B2 (sl)
BR (1) BR9807537B1 (sl)
CA (1) CA2278546C (sl)
DE (1) DE69831223T9 (sl)
DK (1) DK0972520T3 (sl)
EA (1) EA001579B1 (sl)
ES (1) ES2244043T3 (sl)
HU (1) HU226554B1 (sl)
IL (2) IL130967A0 (sl)
NO (1) NO322334B1 (sl)
NZ (1) NZ336509A (sl)
PL (1) PL189381B1 (sl)
RS (1) RS49691B (sl)
SI (1) SI0972520T1 (sl)
TR (1) TR199901832T2 (sl)
WO (1) WO1998033514A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239514T1 (de) † 1997-02-07 2003-05-15 Stryker Corp Matrixlose osteogene vorrichtungen und implantate und verfahren zu deren verwendung
EP1434569A1 (en) * 2001-10-09 2004-07-07 CellFactors plc Therapeutic biological product and method for formation of new vascularised bone
DK1448246T4 (en) 2001-11-19 2015-12-21 Scil Technology Gmbh Homogeneously coated device with osteoinductive and osteoconductive properties
DK1539261T3 (da) 2002-09-10 2006-08-07 Scil Technology Gmbh Metalimplantat belagt under nedsat oxygenkoncentration med osteoinduktiv protein
EP1651272A1 (en) * 2003-08-05 2006-05-03 Fuji Photo Film B.V. Use of recombinant or synthetic gelatin as a stabiliser in vaccines
AU2004288854B2 (en) * 2003-11-10 2009-10-01 Arriva-Pharmaceuticals, Inc. Dry recombinant human alpha 1-antitrypsin formulation
PL1737734T3 (pl) 2004-03-10 2011-02-28 Scil Tech Gmbh Powlekane implanty, ich wytwarzanie i zastosowanie
US20160344677A1 (en) 2015-05-22 2016-11-24 Microsoft Technology Licensing, Llc Unified messaging platform for providing interactive semantic objects
US10360287B2 (en) 2015-05-22 2019-07-23 Microsoft Technology Licensing, Llc Unified messaging platform and interface for providing user callouts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
ATE142460T1 (de) * 1991-06-21 1996-09-15 Genetics Inst Osteogene proteine enthaltende arzneimittel
JP2966592B2 (ja) * 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
NZ249113A (en) * 1992-02-12 1996-07-26 Bioph Biotech Entw Pharm Gmbh Recombinant dna encoding tgf-b, its production and pharmaceutical compositions thereof
CA2093836A1 (en) * 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
DE69524456T2 (de) * 1995-03-21 2002-08-01 Applied Research Systems Flüssige hcg-formulierungen
PL186518B1 (pl) * 1995-04-19 2004-01-30 Bioph Biotech Entw Pharm Gmbh Białko, kompozycja farmaceutyczna i sposób wytwarzania białka

Also Published As

Publication number Publication date
CA2278546A1 (en) 1998-08-06
JP4209948B2 (ja) 2009-01-14
AU5679198A (en) 1998-08-25
BR9807537B1 (pt) 2009-01-13
EP0972520A1 (en) 2000-01-19
EA199900694A1 (ru) 2000-04-24
DE69831223D1 (de) 2005-09-22
EP0972520A4 (en) 2002-11-05
HUP0002386A2 (hu) 2000-11-28
DE69831223T9 (de) 2006-12-07
NZ336509A (en) 2001-03-30
NO993702L (no) 1999-09-29
PL189381B1 (pl) 2005-07-29
EA001579B1 (ru) 2001-06-25
IL130967A (en) 2006-12-10
EP0972520B9 (en) 2006-03-22
WO1998033514A1 (fr) 1998-08-06
YU34999A (sh) 2002-08-12
CN1152712C (zh) 2004-06-09
PL334852A1 (en) 2000-03-27
AP983A (en) 2001-07-16
BR9807537A (pt) 2000-03-21
IL130967A0 (en) 2001-01-28
CN1244127A (zh) 2000-02-09
DK0972520T3 (da) 2005-12-19
AU737595B2 (en) 2001-08-23
ES2244043T3 (es) 2005-12-01
EP0972520B1 (en) 2005-08-17
RS49691B (sr) 2007-12-31
HUP0002386A3 (en) 2002-09-30
ATE302021T1 (de) 2005-09-15
KR100548107B1 (ko) 2006-02-02
DE69831223T2 (de) 2006-02-16
HU226554B1 (en) 2009-03-30
AP9901602A0 (en) 1999-09-30
KR20000070586A (ko) 2000-11-25
CA2278546C (en) 2008-04-01
NO993702D0 (no) 1999-07-29
NO322334B1 (no) 2006-09-18
TR199901832T2 (xx) 1999-12-21

Similar Documents

Publication Publication Date Title
AU3866097A (en) Naphtholactams and lactones as bone morphogenetic protein active agents
EG22500A (en) Use of an encapsulated bioactive composition
HUP9902187A3 (en) Diaphysial cortical dowel
EP1047442A4 (en) BONE MORPHOGENETIC PROTEINS AND THEIR USE IN BONE GROWTH
ZA989461B (en) Methods and compositions for the treatment of autoimmune disease using heat shock proteins
HUP9802556A3 (en) Use of bone morphogenetic protein (bmp) for regeneration of functional connection of bone and tendon or ligament
EP1039801A4 (en) 207 HUMAN SECRETED PROTEINS
PL339463A1 (en) April - novel protein of growth promoting action
EP1000084A4 (en) 123 PROTEIN SEPARATED BY HUMAN
EP0975371A4 (en) ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR MODULATING THE ACTIVATING PROTEIN 1.
EP1095159A4 (en) Bone Morphogenetic Protein
EP1040117A4 (en) 110 HUMAN SECRETATED PROTEINS
EP1019091A4 (en) 50 SECRETED PROTEINS OF HUMAN ORIGIN
EP1005544A4 (en) 70 HUMAN, SECRETED PROTEINS
HUP9603373A3 (en) Cosmetic composition for artificial tanning and its use
IL130967A0 (en) Freeze-dried composition of bone morphogenetic protein human mp52
EP1027430A4 (en) SERIES OF 64 HUMAN SECRETED PROTEINS
EP1032838A4 (en) 125 HUMAN SECRETED PROTEINS
AU7115996A (en) Uses of bone morphogenetic proteins
EP1009766A4 (en) 19 HUMAN, SECRETED PROTEINS
AU6245898A (en) Injectable formulations for treatment of osteoporotic bone
EP1042674A4 (en) 148 HUMAN SUCKED PROTEINS
EP1002132A4 (en) HUMAN SECRETED PROTEINS
EP0691349A3 (en) Morphogenetic dimeric proteins of bone origin and their fragments and anologues and pharmaceutical compositions containing them
EP1003763A4 (en) 83 HUMAN SECRETED PROTEINS